Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16898710 | 0.87 | IRAK4 (0.41) | MAPTALDH1A1MEN1KMT2AIRAK4 | |
| SCHEMBL20377768 | 0.85 | L3MBTL3 (0.34) | SLC18A3ALDH1A1MEN1KMT2AIRAK4 | |
| SCHEMBL16898922 | 0.84 | IRAK4 (0.35) | MAPTRAB9AALDH1A1IRAK4TLR8 | |
| SCHEMBL16898992 | 0.84 | MAPT (0.37) | MAPTRAB9AALDH1A1MEN1NPY1R | |
| SCHEMBL16898968 | 0.82 | MAPT (0.51) | SLC18A3MAPTRAB9AALDH1A1MEN1 | |
| SCHEMBL16899130 | 0.81 | GRIA1 (0.49) | MAPTALDH1A1MEN1KMT2AIRAK4 | |
| SCHEMBL16898813 | 0.80 | ALDH1A1 (0.48) | MAPTALDH1A1HSP90AA1POLBSMN1; SMN2 | |
| SCHEMBL25597126 | 0.80 | IRAK4 (0.46) | MAPTALDH1A1IRAK4POLB | |
| SCHEMBL20606659 | 0.78 | IRAK4 (0.47) | ALDH1A1IRAK4SMN1; SMN2 | |
| SCHEMBL16898903 | 0.77 | MAPT (0.47) | MAPTALDH1A1IRAK4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3092226-B1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2019-03-13 | — | — | EP | disclosed |
| US-10160753-B2 | Indazole compounds as IRAK4 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-12-25 | — | — | US | disclosed |
| EP-3092226-A1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2016-11-16 | — | — | EP | disclosed |
| US-20160326151-A1 | Indazole Compounds as IRAK4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-11-10 | — | — | US | disclosed |
| WO-2015104662-A1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160753-B2 | Indazole compounds as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | SLC18A3 4793/4885MAPT 1817/4885RAB9A 3562/4885 |
| US-20160326151-A1 | Indazole Compounds as IRAK4 Inhibitors | IRAK4, IRAK3, IRAK1 | SLC18A3 4793/4885MAPT 1817/4885RAB9A 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.